Global X China Biotech ETF (HKG:9820)
Hong Kong
· Delayed Price · Currency is HKD · Price in USD 6.90
-0.04 (-0.51%)
At close: May 6, 2025, 4:00 PM HKT
12.76% (1Y)
| Assets | n/a |
| Expense Ratio | n/a |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +12.76% |
| Volume | 750 |
| Open | 6.93 |
| Previous Close | 6.93 |
| Day's Range | 6.90 - 6.93 |
| 52-Week Low | 5.15 |
| 52-Week High | 7.91 |
| Beta | n/a |
| Holdings | 10 |
| Inception Date | Jul 25, 2019 |
About 9820
9820.HK was created on 2019-07-25 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Global X China Biotech ETF seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Underlying Index.
Asset Class Equity
Category Health Care
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9820
Provider Global X
Index Tracked Solactive China Biotech Index - CNY - Benchmark TR Net
Performance
9820 had a total return of 12.76% in the past year, including dividends. Since the fund's inception, the average annual return has been -28.96%.
Top 10 Holdings
62.89% of assets| Name | Symbol | Weight |
|---|---|---|
| Innovent Biologics, Inc. | 1801 | 9.83% |
| Jiangsu Hengrui Medicine Co., Ltd. | 600276 | 9.04% |
| WuXi Biologics (Cayman) Inc. | 2269 | 8.65% |
| WuXi AppTec Co., Ltd. | 603259 | 7.68% |
| Akeso, Inc. | 9926 | 6.80% |
| Sino Biopharmaceutical Limited | 1177 | 5.50% |
| Shanghai RAAS Blood Products Co., Ltd. | 002252 | 4.64% |
| Hansoh Pharmaceutical Group Company Limited | 3692 | 3.83% |
| Zai Lab Limited | ZLAB | 3.48% |
| Beijing Tiantan Biological Products Co., Ltd. | 600161 | 3.42% |